Role of Interleukins in Renal, Cardiac
Article Sidebar
Abstract
Interleukins play very important role in renal, cardiac and liver functions. Among 37 interleukins. identified so far, Interleukins 1, 5, 6, 8, 10, 12, 15, 17, 18 & 22 and their associated receptors are linked to majority of the above three organ functions. This review article highlight the recent research findings during the last three decades in this filed.
Interleukins are a group of cytokines first expressed by leukocytes and they play a prominent role as immune modulators. They modulates immune response and direct immune cells to the site of inflammations. Infections produces inflammations which in turn produces interleukins by leukocytes. The number of interleukins identified so far numbering 37 plays significant roles in many inflammatory processes. The research findings during the last two decades on the role of interleukins in renal, cardiac.
Full text article
References
Catalan-Dibene J, McIntyre LL, Zlotnik A. Interleukin 30 to interleukin 40. J Interferon Cytokine Res. 2018; 38: 423-439.
Rubinow DR. Brain, behaviour and immunity: an interactive system. J Natl Cancer Inst Monogr. 1987; 10: 79-82.
Mantovani A, Allavena P, Sica A, et al. Cancer-relatedinflammation. Nature. 2008; 454: 436-444.
Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol. 2009; 27: 485-517.
Lissoni P. Therapy implications of the role of intereluin-2 in cancer. Expert Rev Clin Immunol. 2017; 13: 491-498.
Elkassar N, Gress RE. An overview of IL-17 biology and its use in immunotherapy. J Immunotoxicol. 2010; 1-7.
Towne JE, Renshaw BR, Douangapanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36 alpha, IL-36 beta, and IL-36 gamma) or antagonist (IL-36Ra) activity. J Biol Chem. 2011; 286: 42594-42602.
Boraschi D, Lucchesi D, Hainzl S, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw. 2011; 22: 127-147.
Dinarello CA, Kaplanski G. Interleukin-18 treatment options for inflammatory diseases. Expert Rev Clin Immunol. 2005; 1: 619-632.
Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and anti-inflammatory role for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003; 198: 1951-1957.
Lissoni P, Barni S, Tisi E, et al. In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer. Eur J Cancer: 1993; 29A: 1127-1132.
Walmsley M, Butler DM, Marinova-Mutafchieva L, et al. An anti-inflammatory role for interleukin-11 in established murine collage-induced arthritis. Immunology. 1998; 95: 31-37.
Cavaillon JM. Pro- versus anti-inflammatory cytokines: myth or reality. Cell Med Biol. 2001; 47: 695-702.
Elkassar N, Gress RE. An overview of IL-7 biology and its use in immunotherapy. J Immunotoxicol. 2010; 7: 1-7.
Waldmann TA. Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol. 2014; 10: 1689-1701.
Gollob JA, Veenstra KG, Parker RA, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol. 2003; 21:2564-2573.
Lissoni P, Barni S, Mandalà M, et al. Immunobiological effects of interleukin-2, interleukin-12 or interleukin-2 plus interleukin-12 in metastatic cancer patients. Int J Immunotherapy XIV. 1998; 41-44.
Dennis KL, Blatner NR, Gounari F, et al. Current status of IL-10 and regulatory T cells in cancer. Curr Opin Oncol. 2013; 25: 637-645.
Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr. 2006; 83: 447S-4555.
Banks RE, Patel PM, Selby PJ. Interleukin-12: a new clinical player in cytokine therapy. Br H Cancer. 1995; 71: 655-659.
Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007; 26: 371-381.
He J, Zhang X, Li Z. Low-dose interleukin-2 treatment selectively modulates CD4+ T cells subsets in patients with systemic lupus erythematosus. Nat med. 2016; 22: 991-993.
Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation. Immunity. 2019; 50: 798-811.
Redrup AC, Howard BP, MacGlashan DW Jr, et al. Differential regulation of IL-4 and IL-13 secretion by human basophils: their relationship to histamine release in mixed leukocyte cultures. J Immunol. 1998; 160: 1957-1964.
Andoh A, Hata K, Araki Y. Interleukin (IL)-4 and IL-17 synergistically stimulate IL-6 secretion in human colonic myofibroblasts. Int J Mol Med. 2002; 10: 631-634.
Damas P, Ledoux D, Nys M, et al. Cytokine serum levels during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992; 215: 356-362.
Jiang Q, Li WQ, Aiello FB, et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev. 2005; 16: 513-533.
Kasahara T, Mukaidu N, Yamashita K, et al. IL-1 and TNF-alpha induction of IL-8 and monocyte chemotactic activating factor (MCAF) mRNA expression in a brain astrocytoma cell line. Immunology, 1991; 74:60-67.
Fischer M, Bijman M, Molin D, et al. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia. 2003; 17: 2513-2516.
Elyaman W, BradshaWem, Uyttenhove C, et al. IL-9 induces. differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci Usa. 2009; 106: 12885-12890.
Visekruna A, Ritter J, Scholz T, et al. Tc9 cells, a new subset of CD8+ T cells, support Th2-mediated airway inflammation. Eur J Immunol. 2013; 43: 606-618.
Goldman SJ. Preclinical biology of interleukin-11: a multifunctional hematopoietic cytokine with potential thrombopoietic activity. Stem Cells Dayt. 1995; 13: 462-471.
Ballaun C. Interleukin 14. In Handboock of Immunopharmacology. 1998; 217-219.
Mathy NL, Scheuer W, Lanzendorfer M, et al. Interleukin 16 stimulates. the expression and production of proinflammatory cytokines by human monocytes. Immunology. 2000; 100: 63-69.
Kryczek L, Wei S, Vatan L, et al. Cutting edge: opposite effects of IL1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediate suppression. J Immunol. 2007; 179: 1423-1426.
Chen Z, Tato CM, Muul L, et al. Distinct regulation of IL-17 in human helper T lymphocytes. Arthritis Rheum56. 2007; 2936-2946.
McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006; 27: 17-23
Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 201: 233-240.
Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009; 206: 1457-1464.
Wawronsky S, Druszczynska M, Kowalewicz-Kulbat M, et al. Interleukin-18 (IL-18) as a target for immune intervention. Acta Biochim Pol. 2016; 63: 59-63.
Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. SeminNephrol. 2007; 27: 98-114.
Leng RX, Pan HF, Tao JH, et al. IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases. Expert Opin Ther Targets. 2011; 15: 119-126.
Jain S, Gabunia K, Kelemen SE, et al. The anti-inflammatory cytokine interleukin 19 is expressed in and angiogenic for human endothelial cells. Arteroscler Thromb VascBiol. 2010; 31: 167-175.
Wei CC, Hsu YH, Li HH, et al. IL-20: biological functions and clinical implications. J Biomed Sci. 2006; 13: 601-602.
Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol. 2007; 178: 732-739.
Tian Y, Yuan C, Ma D, et al. IL-21 and IL-12 inhibit differentiation of T reg and TH17 cells and enhance cytotoxicity of peripheral blood mononuclear cells in patients with cervicakl cancer. Int J Gynecol Cancer. 2011; 21: 1672-1678.
Battaglia A, Buzzonetti A, Baranello C, et al. Interleukin-21 (IL-21) synergizes with IL-2 to enhance T cell receptor-induced human T cell proliferation and counteracts IL-2/transforming growth factor-beta-induced regulatory T cell development. Immunology. 2013; 139: 109-120.
Wolk K, Witte E, Witte K, et al. Biology of interleukin-22. SeminImmunopathol. 2010; 32: 17-31.
Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol. 2011; 23: 159-163.
Tang C, Chen S, Qion H, et al. Interleukin-23 as a drug target for autoimmune inflammatory diseases. Immunology. 2012; 135: 112-124.
Wang M, Liang P. Interleuin-24 and its receptors. Immunology. 2005; 114: 166-170.
Valizadeh A, Khosravi A, Zadeh LJ, et al. Role of IL-25 in immunity. J Clin Diagn Res. 2015; 9: 1-4.
Itoh T, Hatano R, Komiya E, et al. Biological effects of IL-26 on T cell-mediated skin inflammation, including psoriasis. J Invest Dermatol. 2019; 139: 878-889.
Fitzgerald DC, Zhang GX, El-Behi M, et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol. 2007; 8: 1372-1379.
Wolik K, Witte K, Sabat R. Interleukin-28 and interleukin-29: novel regulators of skin biology. J Interferon Cytokine Res. 2010; 30: 617-628.
Kelm NE, Zhu Z, Ding VA, et al. The role of IL-29 in immunity and cancer. Critical Rev and Hematol. 2016; 106: 91-98.
Stumhofer IS, Laurence A, Wilson EH, et al. Interleukin-27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Imunol. 2006; 7:937-945.
Sorrentino C, Ciummo SL, Cipollone G, et al. Interleukin-30/IL27p28 shapes prostate cancer stem-like cell behavior and its critical role for tumor onset and metastatization. Cancer Res. 2018; 78: 2654-2668.
Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 2006; 118: 930-937.
Felaco P, Castellani ML, De Lutiis MA, et al. IL-32: a newly-discoveredpro inflammatorycytokine. J BiolRegulHomeost Agents. 2009; 23: 141-147.
Yagami A, Orihara K, Morita H, et al. IL-33 mediates inflammatory response in human lung tissue cells.J Immunol. 2010; 185: 5743-5750.
Chen Z, Buki K, Vaaramieni J, et al. The critical role of IL-34 in osteoclastogenesis. PLoS. 2011; 6(4): e18689.
Jimi E, Shuto T, Ikebe T, et al. Basic fibroblast growth factor inhibits osteoclast-like formation. J Cell Physiol. 1996; 168: 395-402.
Bezie S, PIcarda E, Ossart J, et al. IL-34 is a T reg-specific cytokine and mediates transplant tolerance. J Clin Invest. 2015; 125: 3952-3964.
Galligan CL, Fish EN. Interleukin-34 promotes fibrocyte proliferation. I Interferon Cytokine Res. 2017; 37: 440-448.
Wirtz S, Billmeier U, McHedlidze T, et al. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology. 2011; 141: 1875-1886.
Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36 alpha, IL-36 beta, and IL-36 gamma) or antagonist (IL-36Ra) activity. J Biol Chem. 2011; 286: 42594-42602.
Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010; 11: 104-1022.
Rudloff I, Godsell J, Nold-Petry CA, et al. Brief report: interleukin-38 exerts anti-inflammatory functions and it is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol. 2015; 67: 3219-3225.
Wang X, Wei Y, Xiao H, et al. A novel 23p19/Ebi3 (IL-39) cytokine mediates inflammation in lupus-like mice. Eur J Immunol. 2016; 46: 1343-1350.
Sonoda E, Matsumoto R, Hitoshi Y, et al. Transforming growth factor-beta induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med. 1989; 170: 1415-1420.
Abramo G, Crivelli N. Cabalistic comment to "Shir ha-Shirim". ebook (ed) Rome Italy 1995.
Authors
Copyright (c) 2025 Journal of Current Medical Research and Opinion
This work is licensed under a Creative Commons Attribution 4.0 International License.